Dr. John Heinzerling from SERO presents findings on a large institutional experience with stereotactic ablative radiation therapy (SBRT) for early stage lung cancer at this year’s annual ASTRO meeting. This large experience suggested results and outcomes that were comparable to previous national trials showing the expertise of SERO in the delivery of this highly technical, advanced therapy.
COVID-19 Update – SERO is open. We continue to consult, evaluate and treat patients and their families at our existing locations.
Dr. John Heinzerling Presents Findings with Stereotactic Ablative Radiation Therapy (SBRT) for Early Stage Lung Cancer
Posted on September 30, 2014 in Lung Cancer
